ClinicalTrials.gg
CompletedNCT01394224Updated Oct 6, 2011

Bioequivalence Study of Levetiracetam Tablet and Intravenous Infusion in Healthy Japanese Subjects

A Phase 1 interventional study of Levetiracetam and Levetiracetam in Healthy Volunteers, sponsored by UCB Pharma. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-06.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the pharmacokinetics(PK) and evaluate the bioequivalence of levetiracetam (LEV) following a single 15-minutes IV infusion of 1500 mg and a single oral dose(tablets) of 1500 mg in healthy Japanese subjects.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
  • Japanese
03

In context

Lead sponsor

UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Japanese male and female volunteers with the age between 20 and 55 years old

Exclusion criteria

Exclusion Criteria:

  • Subject has participated or is participating in any other clinical studies of drug or another IMP within the last 3 months
  • Subject is not healthy (eg, taking any drug treatments, excessive amount of alcohol, cigarettes or caffeine, having any medical or emotional/psychological problems, a drug/alcohol abuse, having abnormal safety parameters)
  • Subject is pregnant or lactating female.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Levetiracetam IV Infusion (1500 mg)

    Drug: Levetiracetam

  • Experimental
    Levetiracetam tablets (1500 mg)

    Drug: Levetiracetam

Interventions

  • Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose

    Also known as: E-Keppra

  • Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose

    Also known as: E-Keppra

06

What researchers measure

Primary outcomes

  1. Maximum drug concentration (Cmax)

    Time frame: Multiple sampling from 0 to 36 hours following single dose

  2. Area under the plasma drug concentration versus time curve from hour 0 to the time with a last quantifiable level (AUCo-t)

    Time frame: Multiple sampling from 0 to 36 hours (could be less than 36 hours if the last quantifiable concentration is below limit of quantification), following single dose

Secondary outcomes

  1. Time to reach maximum plasma concentration (tmax)

    Time frame: Multiple sampling from 0 to 36 hours following single dose

  2. Plasma concentration at the end of infusion (C15' )

    Time frame: At 15 minutes after termination of the15-minutes infusion

  3. Area under the curve from 0 to infinity (AUC)

    Time frame: Multiple sampling from 0 to 36 hours following single dose

  4. Mean resident time (MRT)

    Time frame: Multiple sampling from 0 to 36 hours following single dose

  5. Terminal elimination half-life(t1/2)

    Time frame: Multiple sampling from 0 to 36 hours following single dose

  6. First order terminal elimination rate constant (λz )

    Time frame: Multiple sampling from 0 to 36 hours following single dose

  7. Total body clearance after oral administration (CL/F) or after IV infusion (CL)

    Time frame: Multiple sampling from 0 to 36 hours following single dose

  8. Volume of distribution after oral administration(Vz/F) or after IV infusion(Vz)

    Time frame: Multiple sampling from 0 to 36 hours following single dose

07

Study locations

1 site
  • London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2011
First posted
Jul 14, 2011
Start
Jun 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Last update
Oct 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01394224
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jul 14, 2011
Start date
Jun 2011
Primary completion
Sep 2011
Completion
Sep 2011
Last update
Oct 6, 2011

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion